Propylthiouracil associated with increased risk of serious liver injury
FDA has notified healthcare professionals that there is a risk of serious liver injury, including liver failure or death, with the use of propylthiouracil in both adult and pediatric patients.
FDA has notified healthcare professionals that there is a risk of serious liver injury, including liver failure or death, with the use of propylthiouracil in both adult and pediatric patients.
FDA has received 32 reports (22 in adult patients and 10 in pediatric patients) of serious liver injury in patients treated with propylthiouracil. Among the adult patients, 12 deaths and 5 liver transplants occurred; among the pediatric patients, 1 death and 6 liver transplants occurred.
Propylthiouracil is approved for the treatment of hyperthyroidism and is generally used as second-line therapy except in patients who are allergic to or intolerant of methimazole or in patients who are in their first trimester of pregnancy.
Healthcare professionals should closely monitor propylthiouracil-treated patients for symptoms and signs of liver injury, especially during the first 6 months of therapy.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
